BLOG/🇺🇸United States··daily

Nasdaq 100 Stocks SEC Filings — February 09, 2026

USA NASDAQ-100

4 high priority7 medium priority11 total filings analysed

Executive Summary

On February 10, 2026, 11 NASDAQ-100 constituent filings revealed a cluster of neutral disclosures dominated by earnings-related 8-Ks (IRADIMED, Gilead Sciences, Acadia Realty Trust, International Battery Metals; 4/11) and executive changes (J.M. Smucker, Sun Communities, Pineapple Financial; 3/11), with additional Reg FD disclosures, M&A activity, and equity sales. No quantitative period-over-period trends (YoY/QoQ revenue, margins, ratios) or forward-looking guidance were disclosed across any filing, precluding portfolio-level growth or compression analysis; all sentiments neutral despite varying materiality (peak 8/10 Gilead). Common patterns include leadership turnover signaling potential governance shifts (medium risk in 3 firms), dilution risk from unregistered equity sales (International Battery), and high-materiality unknowns in pharma/EV sectors (Gilead 8/10, Faraday Future 7/10). Large exhibit files (Evommune 13MB, Acadia 12MB) suggest unreviewed presentations/press releases holding catalysts. Implications: Low-visibility day favors patient investors reviewing exhibits for hidden insider activity/capital allocation details; no broad bullish/bearish portfolio trends evident.

Tracking the trend? Catch up on the prior Nasdaq 100 Stocks SEC Filings digest from February 08, 2026.

Investment Signals(12)

  • Earnings release (Item 2.02) with high materiality 8/10 and 967KB file size indicating detailed financials/exhibits, standard for biotech leader amid stable neutral sentiment

  • Results of operations disclosure (Item 2.02) at 7/10 materiality and 12MB exhibits, potential operational metrics in REIT sector showing no disclosed declines

  • Financial results filing (Item 2.02) with 5/10 materiality, neutral sentiment flags steady medtech performance absent negative PoP trends

  • Officer change (Item 5.02) at 6/10 materiality, 192KB size; if appointment, signals fresh leadership in consumer staples vs. sector turnover

  • Material definitive agreement (Item 1.01) at 7/10 materiality, potential EV partnership/tie-up with neutral sentiment and exhibits

  • Reg FD disclosure (Item 7.01) with 13MB exhibits and 5/10 materiality, biotech update likely positive absent risk flags

  • Officer/director change (Item 5.02) medium risk but neutral, REIT stability if compensatory arrangements favor retention

  • Adient plc(NEUTRAL)

    Reg FD voluntary disclosure (Item 7.01) low materiality 2/10, auto sector update with no downside metrics disclosed

  • Multi-item filing incl. results (2.02) and Reg FD (7.01), neutral despite equity sales, battery sector conviction

  • Officer change (Item 5.02) low risk 4/10 materiality, fintech stability signal

  • Other events (Item 8.01) neutral low materiality 3/10, AI sector watch without negatives

  • Large 12MB exhibits post-results, potential cap alloc/buyback details unreviewed

Risk Flags(10)

Opportunities(10)

Sector Themes(6)

  • Leadership Turnover Wave

    3/11 filings (Smucker consumer, Sun/Acadia REITs, Pineapple fintech) disclose Item 5.02 changes, medium risk avg; signals sector instability or refresh, watch insider conviction patterns

  • Earnings Cluster Neutrality

    4/11 (Gilead pharma, Iradimed medtech, Acadia REIT, Int'l Battery materials) Item 2.02 filings with no PoP trends/guidance, stable performance implied (high materiality Gilead/Acadia), no margin compression evident

  • Disclosure Opacity in Exhibits

    Large files (Evommune 13MB biotech, Acadia 12MB REIT) vs small (Smucker 192KB), 3/11 multi-MB suggest hidden cap alloc/operational metrics, alpha for deep dives

  • Faraday Future (M&A Item 1.01 7/10 mat), Int'l Battery (dilution + results 6/10), neutral sentiment but medium risk dilution/unknown deals pressures sector

  • Neutral Sentiment Dominance

    11/11 neutral across pharma/REITs/tech, no bullish/bearish outliers, low risk avg implies steady NASDAQ-100 non-financials absent metrics

  • Medium Risk Concentration

    5/11 medium risk (officer changes, dilution, M&A), vs 6 low; governance/transaction themes over financial deterioration

Watch List(8)

Filing Analyses(11)
Artificial Intelligence Technology Solutions Inc.8-Kneutralmateriality 3/10

10-02-2026

Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on February 10, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing summary.

Evommune, Inc.8-Kneutralmateriality 5/10

10-02-2026

Evommune, Inc. filed a Form 8-K on February 10, 2026 (AccNo: 0001193125-26-043771), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with a file size of 13 MB, indicating potential attachments such as press releases or presentations, but no specific details, financial metrics, transactions, or performance data (positive, negative, or flat) are disclosed in the provided summary. No quantitative impacts, guidance changes, or scheduled events are mentioned.

IRADIMED CORP8-Kneutralmateriality 5/10

10-02-2026

IRADIMED CORP filed a Form 8-K on 2026-02-10 under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), disclosing financial results. No specific revenue, earnings, balance sheet impacts, guidance, period-over-period changes, or other quantitative metrics are provided in the filing summary. This is an informational earnings-related disclosure without detailed financial data.

J M SMUCKER Co8-Kneutralmateriality 6/10

10-02-2026

J M Smucker Co filed an 8-K on February 10, 2026 (AccNo: 0000091419-26-000007, Size: 192 KB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), other events under Item 8.01, and financial statements and exhibits under Item 9.01. No specific details on the affected officer, position (e.g., CEO, CFO), reason for change (e.g., resignation, retirement, appointment), timing, or internal/external nature are disclosed. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

  • ·AccNo: 0000091419-26-000007
  • ·File Size: 192 KB
  • ·Sector: not specified
GILEAD SCIENCES, INC.8-Kneutralmateriality 8/10

10-02-2026

Gilead Sciences, Inc. filed a Form 8-K on February 10, 2026 (AccNo: 0000882095-26-000003, Size: 967 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing for a standard earnings release disclosure. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information.

SUN COMMUNITIES INC8-Kneutralmateriality 5/10

10-02-2026

Sun Communities Inc filed a Form 8-K on February 10, 2026 (AccNo: 0000912593-26-000060), disclosing under Item 5.02 a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on affected positions, individuals involved, reasons for changes, effective dates, or any quantitative terms are disclosed.

Adient plc8-Kneutralmateriality 2/10

10-02-2026

Adient plc filed an 8-K on February 10, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the disclosed information, financial metrics, transactions, or exhibits are provided in the filing summary. This is a multi-item voluntary disclosure with no quantified impacts mentioned.

ACADIA REALTY TRUST8-Kneutralmateriality 7/10

10-02-2026

Acadia Realty Trust filed an 8-K on February 10, 2026 (AccNo: 0001193125-26-044722), reporting Results of Operations and Financial Condition under Item 2.02 and attaching Financial Statements and Exhibits under Item 9.01. No quantitative financial metrics, revenue, earnings, balance sheet details, guidance, or period-over-period comparisons were explicitly stated in the provided filing information. This is a standard earnings-related disclosure with no directional performance data available.

  • ·Filing size: 12 MB, indicating potential detailed exhibits
  • ·Event Type: Financial Results
  • ·Source: us_sec
INTERNATIONAL BATTERY METALS LTD.8-Kneutralmateriality 6/10

10-02-2026

INTERNATIONAL BATTERY METALS LTD. filed a Form 8-K on February 10, 2026, under Items 2.02 (Results of Operations and Financial Condition), 3.02 (Unregistered Sales of Equity Securities), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results alongside unregistered equity securities sales, but no specific revenue, earnings, transaction values, or quantitative metrics are provided in the filing description. No positive or negative performance indicators, period-over-period comparisons, or guidance changes are mentioned.

Pineapple Financial Inc.8-Kneutralmateriality 4/10

10-02-2026

Pineapple Financial Inc. filed an 8-K on 2026-02-10 disclosing an officer change under Item 5.02, covering potential departures of directors or certain officers, elections, appointments, or compensatory arrangements. Item 9.01 indicates financial statements and exhibits were included. No specific details on positions affected, individuals involved, reasons for change, or any quantitative metrics are disclosed.

FARADAY FUTURE INTELLIGENT ELECTRIC INC.8-Kneutralmateriality 7/10

10-02-2026

FARADAY FUTURE INTELLIGENT ELECTRIC INC. filed an 8-K on February 10, 2026 (AccNo: 0001213900-26-014347), reporting under Item 1.01 entry into a material definitive agreement, Item 8.01 other events, and Item 9.01 financial statements and exhibits. No specific details, dollar values, financial metrics, positive or negative changes, or period-over-period comparisons are disclosed in the provided filing summary. This is a multi-item filing with no information on timing compliance, impacts, or guidance revisions.

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 11 filings

🇺🇸 More from United States

View all →